Should you buy these under-the-radar Woodford holdings?

Edward Sheldon looks at two of Neil Woodford’s lesser known key holdings.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s no secret that Neil Woodford is a fan of both the healthcare and tobacco sectors.

Indeed, Woodford’s top four holdings as at the end of July were none other than AstraZeneca, GlaxoSmithKline, Imperial Brands and British American Tobacco and these four holdings alone made up over 30% of his well renowned Equity Income Fund.  

But what’s becoming increasingly clear is that Woodford is more than happy to look outside the square in his search for undervalued stocks, and a closer look at his top 10 holdings reveals some interesting names.

Here’s a look at two of the lesser known stocks in Woodford’s top 10 holdings.

Provident Financial

The fifth largest holding in Woodford’s Equity Income Fund (4.5% of the fund), is financial services group Provident Financial (LSE: PFG), and it’s not hard to see why Neil is favourable towards the company.

Promoted to the FTSE 100 at the end of 2015, Provident specialises in credit cards, consumer credit and vehicle finance and has been a very strong performer over the last five years, generating annualised total shareholder returns of a huge 28% per year.

The company has an excellent track record of revenue and earnings growth and its dividend has grown significantly in recent years from 64p per share in FY2010 to £1.20 per share in FY2015. At the current share price, Provident is yielding 4.1% but Woodford believes the dividend has the potential to grow “in excess of 10% per annum.”

Woodford has described Provident as an “incredibly well-managed, growing business” and has taken advantage of price weakness this year to add to his holding. Trading on a P/E ratio of 17.4 times next year’s earnings, in my opinion Provident looks reasonable value for a company with such a consistent track record of revenue growth and excellent dividend growth prospects.

Capita

Coming in as the ninth largest holding in Woodford’s fund (2.94% of the fund) is another lesser known stock, Capita (LSE: CPI), which specialises in business process outsourcing and professional services for public and private sector clients.

Another company with a consistent track record, Capita has seen its revenue grow from £2,744m in FY2010 to £4,674m in FY2015, a compounded annual growth rate (CAGR) of 11.2% and its share price enjoyed an excellent run between 2012 and 2015, rising from around 600p to over 1,300p in three years.

However in February this year, the company’s shares fell to a two-year low after it announced that both the value of its bid pipeline and the average length of its contracts had fallen, and the share price has continued to drift lower since, now down almost 14% year-to-date.

An update in May revealed that the company had enjoyed a “solid start to the year” and with the stock trading on an undemanding P/E ratio of 14.1 times next year’s earnings, with a dividend yield of 3.1%, it might be worth following in Neil Woodford’s footsteps and buying on share price weakness.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »